We are pleased to announce that Stefan Almestrand joined Medicover Integrated Clinical Services (MICS) as our new Precision Medicine Business Development Director.
Stefan brings more than 17 years of international experience in diagnostics, precision medicine, and life sciences. He has launched more than 10 products, several at global scale. Most recently, Stefan served as Global Director of Diagnostics & Precision Medicine at Novo Nordisk, leading strategic partnerships in liver and cardiovascular biomarker development and clinical diagnostics. His career spans leadership roles at AstraZeneca, Thermo Fisher Scientific and Nanostring Technologies, as well as founding two companies within the clinical and precision medicine space, giving him a unique perspective from both the pharmaceutical and service provider sides.
On joining Medicover Integrated Clinical Services, Stefan said: “Medicover has a unique footprint making it possible to combine precision medicine, data, and scientific excellence with real world healthcare delivery at scale which is very appealing. I am very motivated to build value within the company by bringing precision medicine initiatives into clinical routine.“
This combination of entrepreneurial drive and corporate leadership will be instrumental in strengthening our precision medicine initiatives and advancing the MICS strategy to support pharmaceutical clinical trials from discovery through to commercialisation for our CRO and Pharma partners.
